Pierre Fabre today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of BRAFTOVI® and MEKTOVI® in combination for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation.

Source link